United States: FDA Approves Sandoz Denosumab Biosimilars - Goodwin Procter LLP
On March 5, Sandoz announced that the FDA approved its denosumab biosimilars, WYOST and JUBBONTI, as interchangeable with Amgen's XGEVA and PROLIA.
Full Article